My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.92 +1.22 (+2.86%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Looking for growth without the hefty price tag? Consider NASDAQ:EXEL. ↗

November 06, 2023

EXELIXIS INC (NASDAQ:EXEL) is showing decent growth, but is still valued reasonably.

Via Chartmill

Where Exelixis Stands With Analysts ↗

November 02, 2023

Via Benzinga

Exelixis (EXEL) Q3 2023 Earnings Call Transcript ↗

November 02, 2023

EXEL earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Earnings Outlook For Exelixis ↗

October 31, 2023

Via Benzinga

4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

October 28, 2023

Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.

Via The Motley Fool

Topics Stocks

Why Exelixis Stock Is Trading Lower Today ↗

October 23, 2023

Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in

Via Benzinga

Is Exelixis Stock a Buy Now? ↗

October 18, 2023

There is one key reason to consider the stock.

Via The Motley Fool

14 Analysts Have This to Say About Exelixis ↗

October 11, 2023

Via Benzinga

2 Top Biotech Stocks Defying the Bear Market ↗

September 15, 2023

The best may be yet to come for these companies.

Via The Motley Fool

The Latest Analyst Ratings for Exelixis ↗

September 13, 2023

Via Benzinga

3 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

October 19, 2023

These three lesser-known biotech companies are profitable and growing revenue.

Via The Motley Fool

Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. ↗

October 13, 2023

EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.

Via Chartmill

Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains ↗

October 02, 2023

Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2023 ↗

September 26, 2023

Via Benzinga

Where Exelixis Stands With Analysts ↗

August 22, 2023

Via Benzinga

Analyst Expectations for Exelixis's Future ↗

August 02, 2023

Via Benzinga

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 20, 2023

Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.

Via InvestorPlace

Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy ↗

September 16, 2023

Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule...

Via Talk Markets

4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

September 16, 2023

A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.

Via The Motley Fool

Topics Stocks

The Top Healthcare Stocks to Buy With $100 ↗

August 30, 2023

Both stocks have outperformed the broader market in the last 12 months.

Via The Motley Fool

Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest ↗

August 24, 2023

Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the...

Via Benzinga

Exelixis (EXEL) Q2 2023 Earnings Call Transcript ↗

August 02, 2023

EXEL earnings call for the period ending June 30, 2023.

Via The Motley Fool

2 No-Brainer Biotech Stocks to Buy Right Now ↗

August 24, 2023

These two companies make a compelling case for a high price.

Via The Motley Fool

These Are the ONLY 3 Biotech Stocks to Consider in August 2023 ↗

August 21, 2023

These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time.

Via InvestorPlace

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗

August 21, 2023

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs

Via Benzinga

Exelixis Stock Sees Rising Relative Strength Rating ↗

August 14, 2023

On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.

Via Investor's Business Daily

3 Biotech Stocks You’ll Regret Not Buying Soon ↗

August 08, 2023

These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 ↗

August 08, 2023

Via Benzinga

Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil ↗

July 29, 2023

There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today.

Via InvestorPlace

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.